Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAEFRIF: High Dose Rifampicin in TB-HIV Co-infected Patients
NCT03982277Phase 2Completed
- Sponsor
- Makerere University
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin in Tuberculosis (TB) (4 arms), sponsored by Makerere University. Primary endpoints: Measures of model predicted exposure/pharmacokinetic parameters at 6 weeks and Pharmacokinetics of high dose rifampicin on DTG and EFV at 6 weeks. Started Apr 2019; status: completed.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03982277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982277.